Albemarle (NYSE:ALB – Get Free Report) will announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Albemarle Price Performance
Shares of NYSE:ALB opened at $100.57 on Tuesday. The company has a current ratio of 2.67, a quick ratio of 1.75 and a debt-to-equity ratio of 0.38. Albemarle has a 12 month low of $71.97 and a 12 month high of $153.54. The stock has a market capitalization of $11.82 billion, a PE ratio of -21.26 and a beta of 1.55. The firm has a 50 day moving average of $92.35 and a 200-day moving average of $100.75.
Albemarle Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Friday, December 13th will be paid a $0.405 dividend. This represents a $1.62 dividend on an annualized basis and a dividend yield of 1.61%. The ex-dividend date is Friday, December 13th. Albemarle’s payout ratio is -34.25%.
Analysts Set New Price Targets
Albemarle Company Profile
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.
See Also
- Five stocks we like better than Albemarle
- What is the Euro STOXX 50 Index?
- Intel: Is Now the Time to Be Brave?Â
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Where to Find Earnings Call Transcripts
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.